Tiziana Life Sciences PLC (TLSA:NASDAQ) rocketted at $2, a gain of 21.2%. On Wed, Sep 01, 2021, TLSA:NASDAQ touched a New 2-Week Intraday High of $1.69. The stock got featured on our News Catalysts scanner on Thu, Sep 02, 2021 at 01:40 PM in the 'BIOTECH' category. From Wed, Aug 18, 2021, the stock recorded 50.00% Up Days and 45.45% Green Days
The share price of the company has been moving sideways in recent weeks.
About Tiziana Life Sciences PLC (TLSA:NASDAQ)
Tiziana Life Sciences PLC is involved in the business of developing novel therapeutics for cancer with a focus on late-stage growth and complementary diagnostic tools, with the capability of predicting disease aggressiveness and prognosis in breast cancer patients. The group also has interests, beyond pure oncology, in the discovery and development of monoclonal antibody-based biologics used to benefit patients with inflammatory and auto-immune disorders. The company has a single reporting segment, The Research, and Development of Biotechnological and Pharmaceutical Products. Its lead compound, milciclib (TZLS-201), is a molecule which blocks the action of specific enzymes involved in cell division as well as a number of other protein kinases.
Top 10 Gainers:
- LWAC (LWAC:NASDAQ), 92.95%
- AGIL (AGIL:NASDAQ), 69.4%
- Sphere 3D Corp. (ANY:NASDAQ), 41.78%
- BTCM (BTCM:NYSE), 35.19%
- LGL Systems Acquisition Corp. (DFNS:NYSE), 26.85%
- RAAS (RAAS:NYSE), 21.84%
- Tiziana Life Sciences PLC (TLSA:NASDAQ), 21.21%
- STAB (STAB:NASDAQ), 21.15%
- SCPS (SCPS:NASDAQ), 20.76%
- VERA (VERA:NASDAQ), 20.45%